Pancreas Data 'Overpower'? Celgene Phase III: More Later
By Randy Osborne
Monday, November 12, 2012
Top-line data from a Phase III trial with Abraxane plus gemcitabine in pancreatic cancer by Celgene Corp.'s subsidiary Celgene International Sàrl suggested a benefit over the chemotherapy agent alone in overall survival (OS).
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.